Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,727 across all filing types
Latest filing 2019-05-22 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
公开发行可转换公司债券之债券持有人会议规则
Regulatory Filings Classification · 95% confidence The document is titled as rules for the bondholders' meeting of a convertible bond issued by Kunming Pharmaceutical Corporation. It details the organization, rights, obligations, meeting procedures, voting, and resolutions related to the bondholders' meetings. It references regulatory bodies such as the China Securities Regulatory Commission and Shanghai Stock Exchange rules. The document is a formal set of meeting rules and procedures for bondholders, not a report of financial results, audit, or management changes. It is not an announcement of voting results but the rules governing such meetings. It is a regulatory compliance document related to bondholder governance and meeting procedures. Therefore, it fits best under Regulatory Filings (RNS) as it is a regulatory announcement and compliance document that does not fit other specific categories like Annual Report, Audit Report, or Capital Update.
2019-05-22 Chinese
关于公司未来三年（2019-2021年）股东分红回报规划的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Kunming Pharmaceutical Corporation regarding its future three-year (2019-2021) shareholder dividend return plan. It outlines principles, conditions, and procedures for dividend distribution, including cash and stock dividends, and the approval process involving the board and shareholders. The document is a formal announcement of a planned dividend policy and requires shareholder meeting approval. It does not contain actual financial statements or results, nor is it a report or presentation. It is not a notice of dividend amount for a specific dividend payment but a policy plan announcement. Given the content and length (2259 characters), it fits best as a Regulatory Filing (RNS) because it is a regulatory announcement about dividend policy planning rather than a dividend payment notice (DIV) or a full report. The document is not a report publication announcement since it contains substantive policy details rather than just a notice of report availability.
2019-05-22 Chinese
公开发行可转换公司债券募集资金使用的可行性分析报告
Capital/Financing Update Classification · 95% confidence The document is a detailed feasibility analysis report for the use of funds raised from a public issuance of convertible corporate bonds by Kunming Pharmaceutical Group Co., Ltd. It includes extensive descriptions of investment projects, such as innovative drug and high-end generic drug R&D platforms, marketing digital collaboration platform construction, investment plans, project implementation progress, and expected benefits. The content focuses on capital expenditure plans, project necessity, feasibility, and strategic alignment with company goals. There is no indication that this is an announcement of a report publication, a certification, or a brief summary. It is not a financial statement or earnings release but a detailed capital/financing update related to fundraising and use of proceeds. Therefore, the document fits best under the category of Capital/Financing Update (CAP).
2019-05-22 Chinese
前次募集资金使用情况的鉴证报告
Regulatory Filings
2019-05-22 Chinese
九届六次监事会决议的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement of resolutions passed by the Supervisory Board of Kunming Pharmaceutical Group Co., Ltd. regarding the company's plan to publicly issue convertible bonds. It includes detailed terms of the bond issuance, voting results, authorization requests for the board to handle issuance matters, and references to submission to the shareholders' meeting and regulatory approval by the China Securities Regulatory Commission. The document is lengthy (over 10,000 characters) and contains substantive content about the financing plan, bond terms, and corporate governance related to the issuance. It is not a full financial report, audit report, or earnings release, but rather a comprehensive update on capital raising activities and related corporate decisions. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2019-05-22 Chinese
非经营性损益、净资产收益率、每股收益明细表的鉴证报告
Regulatory Filings
2019-05-22 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.